Market Cap | 94.57M | P/E | - | EPS this Y | 74.50% | Ern Qtrly Grth | - |
Income | -59.49M | Forward P/E | -1.70 | EPS next Y | 31.10% | 50D Avg Chg | 1.00% |
Sales | 1.68M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -17.00% |
Dividend | N/A | Price/Book | 1.02 | EPS next 5Y | - | 52W High Chg | -97.00% |
Recommedations | 2.50 | Quick Ratio | 5.82 | Shares Outstanding | 78.60M | 52W Low Chg | 42.00% |
Insider Own | 23.26% | ROA | -35.84% | Shares Float | 26.11M | Beta | 2.05 |
Inst Own | 54.20% | ROE | -70.32% | Shares Shorted/Prior | 176.06K/47.03K | Price | 1.21 |
Gross Margin | 51.19% | Profit Margin | - | Avg. Volume | 200,525 | Target Price | 0.65 |
Oper. Margin | -1,551.80% | Earnings Date | - | Volume | 16,843 | Change | 0.00% |
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. Akili, Inc. was founded in 2011 and is headquartered in Boston, Massachusetts.
Credit Suisse | Outperform | Aug 11, 23 |
Morgan Stanley | Equal-Weight | Jan 25, 23 |
Morgan Stanley | Equal-Weight | Dec 28, 22 |
B of A Securities | Neutral | Nov 18, 22 |
Credit Suisse | Outperform | Nov 15, 22 |
Credit Suisse | Outperform | Oct 25, 22 |
Cowen & Co. | Outperform | Sep 6, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Studer Jacqueline | Chief Legal Officer Chief Legal Officer | Sep 11 | Sell | 1.05 | 1,130 | 1,186 | 348,292 | 09/14/23 |
Martucci Walter Edward II | Chief Executive Offi.. Chief Executive Officer | Sep 11 | Sell | 1.05 | 2,353 | 2,471 | 3,150,180 | 09/14/23 |
Franklin Matthew | President & COO President & COO | Sep 11 | Sell | 1.05 | 1,728 | 1,814 | 753,898 | 09/14/23 |
Shanbhag Santosh | Chief Financial Offi.. Chief Financial Officer | Sep 11 | Sell | 1.05 | 830 | 872 | 323,636 | 09/14/23 |